The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Renal Denervation
One of the immutable rules of device company development is that success takes many paths. No matter the clinical space a company start out in, it is bound to encounter unexpected obstacles....

The EBI Special Reports Innovation Series helps minimize these unexpected obstacles by carefully hand-picking the most relevant, thought-provoking, and analytical articles for our readers in a given clinical space. The Renal Denervation report contains five articles selected from IN VIVO and Start-Up that detail the growth of this dynamic emerging market.

Articles include:

  • Renal Denervation: Device Market's Gold Rush
    (Start-Up)
  • The Renal Denervation Buzz: Separating Fact From Myth' Covidien Buys Maya Medical (IN VIVO)
  • Masterminds of Ardian: An Interview With Investors Mark Gelfand and Howard Levin (Start-Up)
  • Ardian: Succeeding Where Drugs Fail - Treating Hypertension in the Cath Lab (IN VIVO)
  • Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix (IN VIVO)

Let us be your strategic partner as you receive insider information on innovative new products, profiles on emerging competitors, and the market numbers that could affect your bottom line. Download your copy today and stay ahead of the competition.


No refunds will be given for reports.
Questions? Contact Kristy Kennedy at 480-985-9512 or k.kennedy@elsevier.com.